Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07460986) titled 'A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA' on March 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MedSIR
Condition:
Sarcoma of Soft Tissue
Intervention:
Drug: bexmarilimab
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: July 2026
Target Sample Size: 278
To know more, visit https://clinicaltrials.gov/study/NCT07460986
Published by HT Digital ...